FDA Approves New Interchangeable Biosimilar to Pertuzumab By Ogkologos - December 3, 2025 125 0 Facebook Twitter Google+ Pinterest WhatsApp Approval is based on comparisons across a broad range of structural and functional product quality attributes Source RELATED ARTICLESMORE FROM AUTHOR Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe EMA Recommends Extension of Therapeutic Indications for Ponatinib MOST POPULAR Suggesting a Deadline in the Invitation Letter to FIT Colorectal Cancer... March 31, 2025 Επικοινωνία January 18, 2019 Single Mom Has To Beg For Rides To Doctor For Son... March 14, 2019 Study Estimates That 22% Of Breast Cancers Are Overdiagnosed And Won’t... January 30, 2020 Load more HOT NEWS COVID-19 Is Decimating Nursing Homes, So GreaterGood Has Donated Masks To... Pazopanib Shows Promise for Children, Adults with Soft Tissue Sarcomas Consuming Poultry Could Lower Your Breast Cancer Risk As Much As... Ethnic Diversity and Disparities in Access to Genetic Testing Impact Prostate...
